免疫检查点抑制剂在治疗侵袭性垂体瘤中的研究进展  

Progress of immune checkpoint inhibitors in aggressive pituitary adenomas

作　　者：许宇彤 肖建中[1] Xu Yutong;Xiao Jianzhong(School of Clinical Medicine,Tsinghua University,Department of Endocrinology,Beijing Tsinghua Changgung Hospital,Beijing 102218,China)

机构地区：[1]清华大学附属北京清华长庚医院内分泌科,清华大学临床医学院,北京102218

出　　处：《中华内分泌代谢杂志》2022年第8期688-691,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：垂体瘤是一种常见的中枢神经系统肿瘤,大多数为良性肿瘤,但部分侵袭性垂体瘤对常规治疗反应较差,严重危害患者的健康与生命。近年来,免疫肿瘤治疗发展迅速,被证明在多种恶性肿瘤中具有强大的抗肿瘤作用,也有学者对应用免疫检查点抑制剂治疗侵袭性垂体瘤进行了探索。本文将对从可能的作用机制、目前的研究进展等对此进行综述。Pituitary adenomas(PAs)are the most common types of central nervous system tumors.Although most of them are benign tumors,aggressive PAs are resistant to conventional treatments and thus increase morbidity and mortality.Immunotherapy is a promising treatment and has been applied in treatment of kinds of neoplasms,including aggressive PAs.This review summarizes recent advances of immune checkpoint inhibitors in PAs.

关 键 词：垂体瘤 免疫治疗 免疫检查点抑制剂 

分 类 号：R736.4[医药卫生—肿瘤]